Table 3 Summary of cycle outcomes and utilization of included studies in patient who underwent planned oocyte cryopreservation

Blakemore et al., 2021 [29]

< 35: 8

35-37: 6.6

38-40: 5.3

41-42: 4.9

> 42: 5

< 35: 40

35-37: 44.1

38-40: 36.3

41-42: 33.3

> 42: 25.0

< 35: 72.8

35-37: 77.0

38-40: 73.7

41-42: 66.6

> 42: 78.0

68.8

NA

Live birth (fresh/eSET)

< 35: NA/3

35-37: 3/10

38-40: 3/5

41-42: 2/0

> 42: NA/NA

Cobo et al., 2018 [7]

POC: 2.1 ± 1.6

MOC: 4.1 ± 0.9

POC: 12.1

MOC: 7.4

POC: 83.9

MOC: 81.8

NA

POC: 50.7 per transfer

MOC: 41.4 per transfer

POC: 39.2% per transfer

MOC: 31.0% per transfer

Doyle et al., 2016 [30]

Vitrified: 8.0

Fresh: 0

Vitrified: NA

Fresh: NA

Vitrified: 86.1

Fresh: NA

Vitrified: 69.5

Fresh: 71.7

Vitrified: 54.4 per cycle

Fresh: 45.1 per cycle

Vitrified: 38.6%

Fresh: 36.0%

Fuchs Weizman et al., 2020 [39]

1.8-4.8

12.1-15

85%

66-84%

39-84%

NA

Garcia-Velasco et al, 2013 [31]

POC: 1.7 ± 0.6

MOC: NA

POC: 4.6

MOC: 0.8

POC: 84.8%

MOC: NA

NA

POC: 42.3 per patient

MOC: 25 per patient

POC: 30.7% per patient

MOC: 25% per patient

Gürtin et al., 2019 [33]

POC: 4.8

Non-POC: 0.4

NA

NA

NA

NA

POC: 17.4%

Non-POC: 22.9%

Leung et al., 2021 [34]

< 38: 4.1

≥38: 3.2

< 38: 5.6

≥38: 11.9

Vitrified: 84.9%

Slow: 57.1%

< 38: 78

≥38: 70

< 38: 54.5 (95% CI 37.6-71.5) per transfer

≥38: 39.3 (95% CI 21.2-57.4) per transfer

< 38: 64.0 (95% CI 45.2-82.8) per patient

≥38: 52.4 (95% CI 31.0-73.7) per patient

< 38: 48.5% (95% CI 31.4-65.5) per transfer

≥38: 28.6% (95% CI 11.8-45.3) per transfer

< 38: 56.0% (95% CI 36.5-75.5) per patient

≥38: 38.1% (95% CI 17.3-58.9) per patient

Wennberg et al., 2018 [38]

4.0

15

78

62

NA

36-37: 56% per transfer

38-39: 17% per transfer

≥40: 0% per transfer

36-37: 63% per woman

38-39: 26% per woman

≥40: 0% per woman